Middle East News Digest
SEE OTHER BRANDS

Your daily news update on the Middle East

Middle East News Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.

Press releases published on September 4, 2025

Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project

Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: …

American Tungsten Progresses its IMA Mine Rehabilitation

American Tungsten Progresses its IMA Mine Rehabilitation

Vancouver, BC, Sept. 04, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) American Tungsten is pleased to provide an operational update, as it advances its vision to capitalize on …

Dynacor Provides Corporate Update Including Expansion Progress

Dynacor Provides Corporate Update Including Expansion Progress

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation") is pleased to provide a corporate update covering operations and progress on its expansion plan within West Africa and Latin America. Operational …

Robex Announces Voting Results for 2025 Annual General and Special Meeting of Shareholders

Robex Announces Voting Results for 2025 Annual General and Special Meeting of Shareholders

QUEBEC CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to announce the results of the vote of its annual …

Dynacor fait le point sur ses activités, notamment sur l'avancement de son expansion

Dynacor fait le point sur ses activités, notamment sur l'avancement de son expansion

MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor inc. (TSX : DNG) (« Dynacor » ou la « Société ») est heureuse de fournir une mise à jour sur ses activités et les progrès réalisés dans le cadre de son plan d'expansion en Afrique de l'Ouest et en …

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to …

RetailPro, a Nayax Company, and Onebeat Partner to Transform Inventory from Static Data to Real-Time Profit Engine

RetailPro, a Nayax Company, and Onebeat Partner to Transform Inventory from Static Data to Real-Time Profit Engine

HERZLIYA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Onebeat, the AI-powered inventory optimization platform, and RetailPro, a Nayax  Ltd. Company (Nasdaq: NYAX; TASE: NYAX) and a global leader in retail management software, today announced a strategic …

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative …

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)

Topline Phase 2b Clinical Data Expected in 1H 2026 Trial-in-Progress Presentations Scheduled for ESMO and SNO in Fall 2025 BPM31510 has Received Orphan Drug Designation from the U.S. FDA for the Treatment of GBM BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- …

Brunswick Exploration Starts Maiden Drilling Program at Anatacau Main

Brunswick Exploration Starts Maiden Drilling Program at Anatacau Main

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce that it has begun drilling at the Anatacau Main Project, located in the Eeyou-Istchee James Bay …

Helium Evolution Provides Operations Update

Helium Evolution Provides Operations Update

CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Helium Evolution Incorporated (TSXV:HEVI) ("HEVI" or the "Company"), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, is pleased to provide an …

Koryx Announces Updated PEA Results for the Haib Copper Project, Southern Namibia

Koryx Announces Updated PEA Results for the Haib Copper Project, Southern Namibia

92,000MT ANNUAL PAYABLE CU PRODUCTION (1st 10 Years) $1.81/lb C1 COST and $2.05/lb AISC (1st 10 Years) US$1.351bn AFTER-TAX NPV8% 20.1% AFTER-TAX IRR 23 YEAR MINE LIFE The Haib project is a simple, scalable, advanced-stage, open pit sulphide Cu/Mo project …

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering …

HPQ Achieves Pilot-Scale Milestone in Commercial Fumed Silica Production, Sets Sights on Higher-Value Market Segment

HPQ Achieves Pilot-Scale Milestone in Commercial Fumed Silica Production, Sets Sights on Higher-Value Market Segment

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to report that its …

HPQ atteint une étape clé : production pilote de silice pyrogénée de grade commercial et s’oriente vers des segments à plus forte valeur ajoutée

HPQ atteint une étape clé : production pilote de silice pyrogénée de grade commercial et s’oriente vers des segments à plus forte valeur ajoutée

MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), une entreprise technologique axée sur l’innovation dans le développement de matériaux avancés et de procédés critiques, a le …

Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai

Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai

Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the T cell engager arms of IM1240, a …

Sol-Gel Announces Health Canada Approval of EPSOLAY®

Sol-Gel Announces Health Canada Approval of EPSOLAY®

NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for …

Newcore Gold Drilling Intersects 184 g/t Gold over 1.0 Metre and 3.06 g/t Gold over 13.0 Metres, at the Enchi Gold Project, Ghana

Newcore Gold Drilling Intersects 184 g/t Gold over 1.0 Metre and 3.06 g/t Gold over 13.0 Metres, at the Enchi Gold Project, Ghana

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Newcore Gold Ltd. ("Newcore" or the "Company") (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce additional drill results from the 35,000-metre drill program underway at the Company’s 100% …

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions